Extract from the Product Pipeline - Aderly fileDo you have development or partnership projects in Life Sciences? Are you interested in developing your business in France? Product Pipeline

Do you have development or partnership projects in Life Sciences?Are you interested in developing your business in France?

Product Pipeline in the Lyon Region

Extract from the

2012

2

CONTENTSLyon, one of the main bioclusters in Europe! 3

The Technological Research Institute (TRI) 5

Products Pipeline in the Lyon Region 6

Aderly services and contacts 19

* AlizéPharma 6* Alaxia 6* Biom’up 6* EcrinsTherapeutics 7* ERYtechPharma 7* Eyetechcare 7* Edap-tms 7* FlamelTechnologies 8* Geneuro 9* HLA-Gtechnologies 9

* Khorionyx 9* Imaxio 9* IDDBiotech 9* Metabolys 10* Noraker 10* Poxel 10* OTCFrance 10* TBF 11* Transgene 12

* ADNucleis 13* Alvedia 14* Fluoptics 14

* ImmunID 14* Magnisense 14

* Calixar 15* TheCoSMoCompany 15* ImmunID 16

* Metabolys 16* Novadiscovery 16

I- Therapeutic Products 5

II- Diagnostic Products 13

III- Technological Platforms 15

2 3

Lyon, one of the main bioclusters in Europe!

LYON RHÔNE-ALPES LIFE SCIENCES CLUSTER

KEY WORDSInfectiology, vaccines, diagnostics, delivery

systems, antibodies and proteins, nano-biotechnology, medical technology

1 BILLION €

industrial investment in biotechs between 2007 and 2012

70,000

jobs in the Life Sciences, including 28,000 in

bio-health

20,000

students in the Life Sciences and Healthcare

4,500

researchers in infectiology (2,500), oncology (1,700) and nanobiotechnology

(300)

90

“pure biotech” firms

No. 1

in human and animal vaccines, bacteriological diagnostics and

delivery systems

World

industry leaders

Sanofi-Pasteur, bioMérieux, Mérial, Becton-Dickinson, Genzyme, My-

lan, Covidien, Striker, J&J…

4

The Life Sciences sector in the Lyon Region is dynamic and highly innovative!

This overview is designed to give you an idea about the innovation to be found in the Lyon biocluster, providing a non-exhaustive list of products developed by local companies.

This product pipeline is intended for the stakeholder community of the Life Sciences and is aimed at facilitating partnerships and boosting international collaborations.

This information directly does not claim to be a complete description and is subject to change without notice.

Formoreinformationregardinganyofthesecompanies,pleasecontactADERLY

www.aderly.com

4 5

The Technological Research Institute (TRI)

• Aninnovativemodelofpublic-privatepartnership• Anewapproachforinfectiousdiseasesandmicrobiologyresearch:creationofanew

operatortoboosttechnologicalR&Dandspeedupthetimetomarketofnewproductsandservices

NEW IN LYON!

Founders

+1collegegathering30SMBs

A rapid 3-year start40R&Dprojectslaunched€65Mofprivateinvestmentsfromstakeholdersandlocalauthorities

A promising 9-year prospect10,000jobsgeneratedUpto30to40,000sq.m.ofnewlaboratoriesAcumulativebudgetof€668Mover9years

BIOASTER

6

Company Product Therapeutic area Indication Non

clinic Phase I Phase II Phase III Filing On market

Where+ Partners

Asparec® (PEGylated

r-L-asparaginase)Onco-

hematologyAcute Lymphoblastic

Leukemia (ALL)

AZP-01 (unacylated ghrelin

peptide analog)

Metabolic diseases

Type II Diabetes and vascular complications

Meveol Respiratory, orphan Cystic

ALX 08 Respiratory COPD

ALX 10 Oncology Lung cancer

ALX 06 Respiratory Flu

Cova ABDO Abdominal Prevention of adhesion Europe

Cova ORTHO OrthopedicsPrevention of

adhesion (tenolyses, Neurolysis…)

Europe

Cova CARD cardiac Prevention of adhesion Europe

Cova DURA & SPINE Spine Prevention of

adhesion Europe

Cova MAX Dental Guided tissue regeneration Europe + USA

Matri TM ORTHO Orthopedics Bone-void

filling Europe

Matri TM MAX Dental Bone-void filling Europe

I- Therapeutic Products

6 7



Where+ Partners

ET-D5 Oncology Solid tumors

Tubulin polymeri-zation screening

service

Pharmaceutical industry Screening

HIFU Gastroentero-logy Liver Cancer Inserm U1032 and

Centre Léon Bérard

Graspa® OncologyAcute Lymphoblastic

leukemia (ALL) Relapse & Allergy (Europe)

Graspa® Oncology ALL Elderly (France)

Graspa® Oncology Pancreatic cancer (France)

Grara Hematology Sickle cell Anemia

Grara Oncology Radiotherapy

Immunotherapy platform Immunology Tolerance

inductionImmunotherapy

platform Immunology Vaccination against cancer

Gr-Rnai Immunology Inflammation

EyeOP1 OphthalmologyGlaucoma (High

Intensity Focused Ultrasound)

8



Where+ Partners

COREG CR Cardiovascular Cardiovascular USA GlaxoSmithKline

Micropump aspirin Cardiovascular Cardiovascular Europe

New HavenGenvir

(acyclovir)Infectious diseases Herpes

IFN alpha XL Infectious diseases Hepatitis C

Interleukin 2 XL Oncology Renal cell carcinoma

IFN beta XL CNS Multiple sclerosis Merck Serono

FT-105 Metabolic Type 2 diabetes

Metformin XL Metabolic Type 2 diabetes

Omeprazole XL GI disorders GERD

Co-amoxiclav XR

Infectious diseases

Infectious diseases

Blood clotting factors

Blood and lym-phatic systems Hemophilia Baxter

GLP-1 XL Metabolic Type 2 diabetes

hGH XL Endocrinology Growth disorders

TGF-beta 1 inhibitors Multiple Multiple Digna Biotech

Methylthioade-nosine Multiple Multiple Digna Biotech

THA-902 CNS Pain Theralpha

8 9



Where +Partners

GNbAC1 Neurology / CNS

Multiple sclerosis

GNbAC2 Neurology / Psychiatry Schizophrenia

Peptide derived from HLA-G molecule Transplantation Rejection

prevention

Peptide derived from HLA-G molecule Oncology Haematological

cancersAutologous

globinCosmetic surgery Dermal filler

Human globin Skin repair Chronic wounds

Spirolept® Infectious Disease

Human Leptospirosis

FranceInstitut Pasteur

IMX461 Infectious Disease Tuberculosis Worldwide - Jenner Insti-

tute / Oxford University

IMX294 Animal Health Immuno castration

USDA (United States Department of Agriculture) -

Undisclosed industrial partner

IMX313-Ag Infectious Disease

Nosocomial Infections

Jenner Institute / Oxford University

IMX313-Ag Oncology Undisclosed partner

IMX313-Ag Infectious Disease Malaria

Jenner Institute / Oxford University

Toulouse University

IMX313-Ag Oncology HPV CHU Tours

10



Where + Partners

iDD001Oncology

Autoimmune diseases

Rituxan refractory lymphoma / Pan B

lymphoma & leukemia

iDD002Oncology

Autoimmune diseases

Rituxan refractory lymphoma / Pan B

lymphoma & leukemia

iDD003 Oncology Pan T lymphoma & leukemia

iDD004 Solid tumor Glioma…

MTBL0036 Metabolic disorders Diabetes To be licensed out

GlassBONEOrthopedic Trauma

Cranio-Maxillo-Facial Dental surgery

Graft bone substitute

ActiKER OrthopedicAnterior Cruciate

Ligament reconstruction

ResoKER OrthopedicAnterior Cruciate

Ligament reconstruction

Self-hardening substitute injectable

«Orthopedic Trauma Cranio-Maxillo-Facial

Dental surgery»

Graft bone substitute

Bone grafting device Dental surgery Graft bone

substitute

Imeglimin Metabolic disorders

Type 2 diabetes

OTSA101 Radioimmuno

therapyOncology

Synovial Sarcoma

(Soft Tissue Sarcoma)

France Japan

10 11



Where + Partners

PHOENIX® Cancellous Bone

Chips

Orthopedics, Spine, Dental

Bone-void filling

Europe, Middle East, Americas (except US)


Blocks


Bone-void filling


PHOENIX® Femoral Head

Orthopedics, Spine

Bone-void filling


PHOENIX® Half Femoral Head

Orthopedics, Spine

Bone-void filling


PHOENIX® Spinal Cancellous Bone

Block

Orthopedics, Spine

Bone-void filling


PHOENIX® Cranial Plugs Neurosurgery Bone-void

filling Europe, Middle East, Americas (except US)


Wedge


Bone-void filling



Powder


Bone-void filling


PHOENIX® Cortico-cancellous

Bone LamellasDental Bone-void

filling Europe, Middle East, Americas (except US)

PATHAPHOENIX® Calcium Sulphate +

Cancellous Bone Paste

Orthopedics, Spine, Dental,

Bone-void filling


PATHAOS® Calcium Sulphate

Paste

Orthopedics, Spine, Dental,

Bone-void filling


PHOENIX® DBM & PHOENIX®

DBM+


Bone-void filling + osteoinduction


CARTIPATCH® Orthopedics, Sports Medecine

Autologous Chondrocytes Implants (ACI)


MENISC-T® Orthopedics, Sports Medecine

Meniscal Allograft


TBFIX® plates Orthopedics Tibial Osteotomy


12



Where + Partners

TG4010 Oncology Non Small Cell Lung Cancer Novartis

JX594/TG6006 Oncology Hepatocarci-noma

Jennerex Biotherapeutics

JX594/TG6006 Oncology Metastatic Co-lorectal Cancer

Jennerex Biotherapeutics

TG4001 Infectious disease

Precancerous lesions of the cervix caused by HPV virus

TG4040 Infectious disease

Chronic Hepatitis C

TG4023 Oncology Metastatic Co-lorectal Cancer

TG3003 Oncology Bone Metastasis

Oncolytic virus 2nd generation Oncology Metastatic solid

tumors

HBV therapeutic vaccine

Infectious disease

Chronic Hepatitis B

TB therapeutic vaccine

Infectious disease Tuberculosis

12 13

II- Diagnostic Products

Company Product Diagnostic area Indication Non clinic Clinic Filing On

marketWhere +Partners

Salmonella*(rt PCR kit)

Food, human and animal health Salmonellosis 2010

E.coli O157H7* (rt PCR kit)

Food, human and animal health

Hemolytic-uremic syndrome 2010

Cronobacter sakazakii* (rt PCR kit) Food, infant formula Sepsis, various

diseases 2010

Listera monocytogenes (rt PCR kit)

Food, human and animal health Listeriosis 2012

Staphylococcus aureus (rt PCR kit)

Food, human and animal health

Staphylococcal infection 2012

E.coli spp (rt PCR kit)

Food, human and animal health (ECBU), water Colibacillosis 2011

E.coli des STEC (rt PCR kit)

Food, human and animal health (ECBU)

Hemolytic-uremic syndrome 2011

Enterobactéries (rt PCR kit)

Food, human and animal health (ECBU), water 2012

Streptocoque beta hémolytique (rt PCR kit)

Food, human and animal health (vaginal sample)

Sepsis, various diseases 2012

Chlamydia trachomatis (rt PCR kit)

Human health (vaginal sample) Chlamydia infection 2012

Mycoplasma genitalium (rt PCR kit)

Human health (vaginal sample) Mycoplasma infection 2012

Legionella spp (rt PCR kit)

Food, human and animal health, environment, water Legionnaires' disease 2012

Legionella pneumophila (rt PCR kit) Human health Legionnaires' disease 2012

Pseudomonas aeruginosa (rt PCR kit) Human health Various diseases, hospi-

tal-acquired infections 2012

14

Company Product Diagnostic area Indication Non clinic Clinic Filing On

marketWhere +Partners

Blood typing Veterinary diagnostic Transfusion Worldwide

AngioStamp Surgical imagery Oncology

ImmunTraCkeR (Diagnostic) immunomodulation «immunomonitoring

Divpenia screening»ImmunTraCkeR

(Diagnostic)Oncology

(solid tumors)«immunomonitoring Divpenia screening»

ImmunTraCkeR (Diagnostic)

Infectious Diseases + sepsis

«immunomonitoring Divpenia screening»

ImmunTraCkeR (Diagnostic)

Oncology (Hematolo-gical Malignancies)


Immun'Ig (Diagnostic) Immunomodulation «immunomonitoring Divpenia screening»

Immun'Ig (Diagnostic) Oncology (Hematolo-gical Malignancies)


MIAtroponin In-vitro diagnostics

Point-of-care testing for myocardial infarction

14 15

Company Target Services Applications Technologies Licensing out opportunity

All membrane proteins / anti-gens (GPCRs, Ion channels, Transporters, Cell-surface

proteins, complexes, …)

Sequence identification Target discoveryMass spectroscopy / optimal

membrane fractions preparation (enrichment process)

na

ProductionProtein / Protein interaction

Drug Screening

Conformational Antibodies production

(monoclonal / polyclonal)

Antigen validation for vaccine discovery

Oligomerization level determination

All expression systems (euka-ryotic / prokaryotic / cell-free) Optimized approach to avoid

inclusion bodies

Know How transfer

Non-denaturing extraction from

biological samples or recombinant cell lines

Homemade non denaturing reagents

Multi-step extraction processRational design of detergent

Extraction process license with the supply

of specific homemade reagents

Purification Chromatographic steps: ion exchange / gel filtration / affinity

Know How transfer

Quality control / Functional /

Structural tests

Coomassie Gel / WB / Clear Native Page / Circular Dichroïsm

/ DLS / ITC / FACS / Int or Ext Fluorescence / MS / ...

na

Crystallization tests 3D structure determinationCo-crystallization

Crystallogenesis robot + visualization + diffraction tests na

Industry and academic cus-tomers in need of understan-ding, control

and prediction of complex

systems

A validated three-step approach for the next

generation modeling and simulation of complex

dynamic systems

In-silico project for - Vaccine development - Bioprocess optimization - Patient sorting - Treatment optimisation - Drug efficacy prediction

CoSMo proprietary software platform provides a set of user

friendly tools to design and integrate models, build and run in-silico simulations. Multi-scale and trans-scale modeling technologies

are leveraged to understand molecules, cells, tissues, organs and organisms in their evolutive

environment.

Software licen-sing of modeling and simulation plaftorm and model library.

Research partnership

III- Technological platforms

16

Company Target Services Applications Technologies Licensing out opportunity

Pharmaceutical industries

clinical research

Analysis of Divpenia and immune repertoire combinatorial diversity

Immunomodulation

- Immunomonitoring - Divpenia screening- TCR and BCR diversity analysis

Fee for service

Europe + USA

Oncology (solid tumors)

Infectious Diseases + sepsis

Oncology (Hematological Malignancies)

Immunomodulation

Oncology (Hematological Malignancies)

Pharmaceuti-cal, Agro-food, Chemical and

Cosmetic Industries

Prediction of Safety/Efficacy of test

compoundsPharmacology, Toxicology Metabolic Flux Ananlysis

(Cellular Metabolomics)

High value in-silico

applications for the pharmaceuti-

cal industry

Prediction of drug candidate efficiency over selected populations: - Accelerate PoC / Prioritise compounds in DISCOVERY - Identify responders & op-timise treatment (regimen, duration, dose) to focus trials in CLINIC - Characterise target population & compare cost/effectiveness to demons-trate value to payers during MARKET ACCESS

Drive STOP-GO decisions from early discovery to market

access & post-market

All disease areas (existing project pipeline in

cardiovascular, CNS, oncology, infectious diseases)

- Novadiscovery proprietary technology platform is designed to ensure the optimal transfer of knowledge from bench to clinic geared towards applications in public health and personalised medicine. - Unique expertise in numerical modelling in biology (biomathe-matics, computing) and knowle-dge management applied to drug and biomarker R&D programs.

Strategic Research

Alliances on selected disease

areas to help our partner drive

their R&D

16 17

NOTES

18

NOTES

18 19

Meet ADERLYinformation on the business environ-ment, specification of your needs

Visit LyonADERLY assists you in finding and mee-ting potential clients, R&D partners, clusters, investors… (1-3 day visit)

Choose LyonADERLY provides advice on regulatory and fiscal matters: meetings with lawyers, accoun-tants, …

Find your real estateADERLY looks for the site (buildings, offices, labs, incu-bators…) to meet your needs

Recruit your work-force, relocate employees and their families with help of ADERLY (meetings, administrative formali-ties…)

Follow-upCommunication, local networks, events, aftercare

Specialists in Company set-up and development projects, ADERLY advises and assists you through every step:

Generating RevenueMaking SavingsReducing Risks

20

ADERLY, the Lyon Area Economic Development Agency, is a public-private partnership. Its mission is to support and advise companies at every step of their set-up and development projects. Since it was created in 1974, ADERLY has helped over 1,200 international firms and organizations to set up or develop their operations in the Lyon area, including euronews, Ikea, Interpol, JTEKT, Genzyme, Lafarge, MDS Pharma and Renault Trucks.

LYON AREA ECONOMIC DEVELOPMENT AGENCYPlace de la Bourse - 69289 Lyon Cedex 02 - France

+33 (0)4 72 40 58 31 www.aderly.com / www.investinlyon.com / www.onlylyon.org

You have development or partnership projects in Life Sciences?You are looking for the perfect location to set up your business?

You are interested in developing your business in France?

Contact ADERLY’s experts dedicated to the Life Sciences

Laëtitia FORTINMSc,Biotech,PharmaandDiagnostics

[email protected]

Yukiko VINCENTInward Investment Manager - ASIA

[email protected]

Sandra KAHRIMANMedicalTechnologiesandCosmetology

[email protected]

PhotosCredits:©

Fotolia,©

BriceRobertwww.b-rob.com.ADERLY,M

arch2012

Documents

Extract from the Product Pipeline - Aderly fileDo you have development or partnership projects in Life Sciences? Are you interested in developing your business in France? Product Pipeline